How is PNC-27 administered?
This describes how PNC-27 is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous or IV (research), on a daily in research protocols schedule, generally over highly variable per protocol. Specific dosing is individual and beyond general information, and human evidence for PNC-27 is limited.
Administration at a glance (reference data)
- Route: Subcutaneous or IV (research)
- Schedule: Daily in research protocols
- Cycle length: Highly variable per protocol
- Half-life: ~hours
References
- PNC-27, anticancer peptide that selectively kills HDM-2-expressing cancer cells — Michl J et al., Anticancer Res, 2006
- Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption — Krzesaj P et al., Annals of Clinical and Laboratory Science, 2024
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on PNC-27
Last updated 2026-06-15.